VRTX241206C600000
- 0.05
- 0.000.00%
Vertex Pharmaceuticals Newsroom
TD Cowen Maintains Vertex Pharmaceuticals(VRTX.US) With Buy Rating
Vertex Pharmaceuticals Raised to Buy From Hold by Jefferies
Vertex Pharmaceuticals Analyst Ratings
Jefferies Upgrades Vertex Pharmaceuticals to Buy From Hold, Adjusts Price Target to $550 From $500
Jefferies Upgrades Vertex Pharmaceuticals(VRTX.US) to Buy Rating, Raises Target Price to $550
Evercore ISI Reaffirms Their Buy Rating on Vertex Pharmaceuticals (VRTX)
Bernstein Maintains Vertex Pharmaceuticals(VRTX.US) With Hold Rating, Maintains Target Price $506
RBC Capital Sticks to Their Hold Rating for Vertex Pharmaceuticals (VRTX)
Citi Maintains Vertex Pharmaceuticals(VRTX.US) With Buy Rating, Maintains Target Price $575
Redburn Atlantic Adjusts Vertex Pharmaceuticals Price Target to $570 From $560
Scotiabank Maintains Vertex Pharmaceuticals(VRTX.US) With Hold Rating, Maintains Target Price $486
Citi Maintains Vertex Pharmaceuticals(VRTX.US) With Buy Rating, Maintains Target Price $575
Vertex Pharmaceuticals (VRTX) Receives a Hold From Stifel Nicolaus
Stifel Maintains Vertex Pharmaceuticals(VRTX.US) With Hold Rating, Maintains Target Price $490
Vertex Pharmaceuticals Analyst Ratings
Citi Maintains Vertex Pharmaceuticals(VRTX.US) With Buy Rating, Raises Target Price to $575
Vertex Pharmaceuticals Initiated With a Buy at Citi
Argus Raises Price Target on Vertex Pharmaceuticals to $550 From $530
Vertex Pharmaceuticals Analyst Ratings
J.P. Morgan Maintains Vertex Pharmaceuticals(VRTX.US) With Buy Rating, Announces Target Price $503